BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
Source link
Get latast news super fast
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
Source link